Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05919264 is registered in ClinicalTrials.gov with Parabilis Medicines, Inc. as lead sponsor.

NCT NCT05919264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05919264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Parabilis Medicines, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 23, 2023
Completion date
August 31, 2027
Enrollment
619 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

adamantinomatous craniopharyngioma, cancer, colorectal cancer, desmoid, endometrial carcinoma, familial adenomatous polyposis (fap), hcc, locally advanced solid tumor, metastatic cancer, metastatic castration-resistant prostate cancer, microsatellite instability-high colorectal cancer, microsatellite stable colorectal cancer, prostate cancer, solid tumor, wnt pathway